LEVONORGESTREL AND ETHINYL ESTRADIOL-  levonorgestrel and ethinyl estradiol  kit 美国 - 英文 - NLM (National Library of Medicine)

levonorgestrel and ethinyl estradiol- levonorgestrel and ethinyl estradiol kit

lupin limited - ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u), levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw) - levonorgestrel and ethinyl estradiol tablets usp are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. in a 1-year controlled clinical trial, 4 pregnancies occurred in women 18 to 35 years of age during 809 completed 91-day cycles of levonorgestrel and ethinyl estradiol tablets during which no backup contraception was utilized. this represents an overall use-efficacy (typical user efficacy) pregnancy rate of 1.98 per 100 women-years of use. oral contraceptives are highly effective for pregnancy prevention. table 2 lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. the efficacy of these contraceptive methods, except sterilization, the iud, and norplant® implant system, depends upon the reliability with which they are used. correct and consistent use of methods can result in lower failure rates. source: trussell j, contraceptive efficacy. in hatcher ra, trussell j, stew

NORLEVO-1 levonorgestrel 1.5 mg tablet blister pack 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

norlevo-1 levonorgestrel 1.5 mg tablet blister pack

orion laboratories pty ltd t/a perrigo australia - levonorgestrel, quantity: 1.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; maize starch; colloidal anhydrous silica; lactose monohydrate; povidone - oral emergency contraceptive indicated for use within 72 hours of unprotected intercourse. it should be used only as an emergency measure. women who present for repeated courses of emergency contraception should be advised to consider long-term methods of contraception.

KYLEENA levonorgestrel 19.5 mg intrauterine drug delivery system sachet 澳大利亚 - 英文 - Department of Health (Therapeutic Goods Administration)

kyleena levonorgestrel 19.5 mg intrauterine drug delivery system sachet

bayer australia ltd - levonorgestrel, quantity: 19.5 mg - drug delivery system, intrauterine - excipient ingredients: dimethylsiloxane/methylvinylsiloxane cross linked elastomer - contraception for up to 5 years

QUASENSE- levonorgestrel and ethinyl estradiol 美国 - 英文 - NLM (National Library of Medicine)

quasense- levonorgestrel and ethinyl estradiol

actavis pharma, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - quasense® (levonorgestrel and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy. do not prescribe quasense to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1) ]. have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1) ]. have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1) ]. have cerebrovascular disease [see warnings and precautions (5.1) ]. have coronary artery disease [see warnings and precautions (5.1) ]. have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1) ]. have uncontrolled hypertension [see warnings

INTROVALE- levonorgestrel and ethinyl estradiol 美国 - 英文 - NLM (National Library of Medicine)

introvale- levonorgestrel and ethinyl estradiol

sandoz inc - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - introvaletm (levonorgestrel and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy. do not prescribe introvaletm (levonorgestrel and ethinyl estradiol tablets) to women who are known to have the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)] have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings and precautions (5.1)] have coronary artery disease [see warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rythym diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)] have

SEASONIQUE- levonorgestrel / ethinyl estradiol and ethinyl estradiol kit 美国 - 英文 - NLM (National Library of Medicine)

seasonique- levonorgestrel / ethinyl estradiol and ethinyl estradiol kit

physicians total care, inc. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - seasonique® (levonorgestrel/ethinyl estradiol tablets and ethinyl estradiol tablets) is indicated for use by women to prevent pregnancy. do not prescribe seasonique to women who are known to have the following: - a high risk of arterial or venous thrombotic diseases. examples include women who are known to: smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)]. have deep vein thrombosis or pulmonary embolism, now or in the past [see warnings and precautions (5.1)] have cerebrovascular disease [see warnings and precautions (5.1)] have coronary artery disease [see warnings and precautions (5.1)] have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)] have inherited or acquired hypercoagulopathies [see warnings and precautions (5.1)] have uncontrolled hypertension [see warnings and precautions (5.4)] . have diabetes with vascular

NEXT CHOICE- levonorgestrel tablet 美国 - 英文 - NLM (National Library of Medicine)

next choice- levonorgestrel tablet

rebel distributors corp. - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw) - levonorgestrel 0.75 mg - levonorgestrel tablets are a prescription-only emergency contraceptive, for women age 17 and younger, that can be used to prevent pregnancy following unprotected intercourse or a known or suspected contraceptive failure. this product is not approved for nonprescription use. to obtain optimal efficacy, the first tablet should be taken as soon as possible within 72 hours of intercourse. the second tablet must be taken 12 hours later. progestin-only contraceptive pills (pops) are used as a routine method of birth control over longer periods of time, and are contraindicated in some conditions. it is not known whether these same conditions apply to the levonorgestrel tablets regimen consisting of the emergency use of two progestin pills. pops however, are not recommended for use in the following conditions: - known or suspected pregnancy known or suspected pregnancy - hypersensitivity to any component of the product hypersensitivity to any component of the product there is no information about dependence assoc

SIMPESSE- levonorgestrel and ethinyl estradiol and ethinyl estradiol kit 美国 - 英文 - NLM (National Library of Medicine)

simpesse- levonorgestrel and ethinyl estradiol and ethinyl estradiol kit

aurobindo pharma limited - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - simpesse® (levonorgestrel and ethinyl estradiol tablets and ethinyl estradiol tablets) is indicated for use by females of reproductive potential to prevent pregnancy. simpesse is contraindicated in females who are known to have or develop the following conditions: - a high risk of arterial or venous thrombotic diseases. examples include females who are known to:         –   smoke, if over age 35 [see boxed warning and warnings and precautions (5.1)].         –   have current or history of deep vein thrombosis or pulmonary embolism [see warnings and precautions (5.1)].         –   have cerebrovascular disease [see warnings and precautions (5.1)]         –   have coronary artery disease [see warnings and precautions (5.1)].         –   have thrombogenic valvular or thrombogenic rhythm diseases of the heart (for example, subacute bacterial endocarditis with valvular disease, or atrial fibrillation) [see warnings and precautions (5.1)].         –   have inherited or acquired hypercoagulopathies [see warnings and

LEVONORGESTREL tablet 美国 - 英文 - NLM (National Library of Medicine)

levonorgestrel tablet

lotus pharmaceutical co., ltd. nantou plant - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw) - levonorgestrel 1.5 mg

ASHLYNA- levonorgestrel and ethinyl estradiol and ethinyl estradiol kit 美国 - 英文 - NLM (National Library of Medicine)

ashlyna- levonorgestrel and ethinyl estradiol and ethinyl estradiol kit

glenmark pharmaceuticals inc., usa - levonorgestrel (unii: 5w7sia7yzw) (levonorgestrel - unii:5w7sia7yzw), ethinyl estradiol (unii: 423d2t571u) (ethinyl estradiol - unii:423d2t571u) - levonorgestrel 0.15 mg - ashlyna is indicated for use by females of reproductive potential to prevent pregnancy. ashlyna is contraindicated in females who are known to have or develop the following conditions: risk summary there is no use for contraception in pregnancy; therefore, levonorgestrel and ethinyl estradiol tablets and ethinyl estradiol tablets should be discontinued during pregnancy. epidemiologic studies and meta-analyses have not found an increased risk of genital or non-genital birth defects (including cardiac anomalies and limb-reduction defects) following exposure to cocs before conception or during early pregnancy. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4 percent and 15 to 20 percent, respectively. risk summary contraceptive hormones and/or metabolites are present in human milk. cocs can reduce milk production in breastfeeding females. this reduction can occur at any time but is less likely to occur once breastf